Clinical Trials: From the Editor
PARP with PD-1/PD-L1 inhibition: Is There Any Magic to the Combination in a Molecularly Unselected Patient Population?
Is Testosterone Such a Bad Thing for Prostate Cancer? Rationale for Using Supraphysiologic Testosterone to Treat Castration-Resistant Prostate Cancer
Clinical Trial Updates of Single-Agent PARP Inhibitor Use in Homologous Recombination Deficient Prostate Cancer Populations
Are More Indications for Local Therapy of Prostate Cancer on the Horizon?
Sipuleucel-T… Beyond the IMPACT Trial
Prostate-Specific Membrane Antigen (PSMA)-Targeted Radioligand Therapies are Finally Arriving
Why Aren’t There More Systemic Therapy Trials for Patients with Muscle-invasive Urothelial Carcinoma of the Bladder?
Just recently, we discussed neoadjuvant systemic therapy for cisplatin-ineligible patients with muscle-invasive urothelial carcinoma of the bladder.1 For those patients “unfit” for cisplatin with at least one of the following criteria: creatinine clearance <60 ml/min, grade ≥2 hearing loss, grade ≥2 neuropathy, ECOG performance status 2, and/or New York Heart Association Class III heart failure,2 there are no good options other than cystectomy alone. Yet, we know the outcomes are not ideal for these patients with cystectomy alone. Finding systemic therapies that may improve outcomes for these patients is clearly an unmet need in the field.